[go: up one dir, main page]

ATE159031T1 - Antigene sowie verfahren zu deren herstellung - Google Patents

Antigene sowie verfahren zu deren herstellung

Info

Publication number
ATE159031T1
ATE159031T1 AT90307900T AT90307900T ATE159031T1 AT E159031 T1 ATE159031 T1 AT E159031T1 AT 90307900 T AT90307900 T AT 90307900T AT 90307900 T AT90307900 T AT 90307900T AT E159031 T1 ATE159031 T1 AT E159031T1
Authority
AT
Austria
Prior art keywords
protein
particle
hepatitis
residues
followed
Prior art date
Application number
AT90307900T
Other languages
English (en)
Inventor
Martin Comberbach
Nigel Harford
Teresa Cabezon
Apolonia Rutgers
Pierre Voet
Eric Jacobs
Cornelis P Hollenberg
Zbigniew A Janowicz
Armin J Merckelbach
Original Assignee
Smithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Biolog filed Critical Smithkline Biolog
Application granted granted Critical
Publication of ATE159031T1 publication Critical patent/ATE159031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT90307900T 1989-07-25 1990-07-19 Antigene sowie verfahren zu deren herstellung ATE159031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38534289A 1989-07-25 1989-07-25
US38918489A 1989-08-03 1989-08-03

Publications (1)

Publication Number Publication Date
ATE159031T1 true ATE159031T1 (de) 1997-10-15

Family

ID=27010975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90307900T ATE159031T1 (de) 1989-07-25 1990-07-19 Antigene sowie verfahren zu deren herstellung

Country Status (22)

Country Link
EP (1) EP0414374B1 (de)
JP (1) JP3069907B2 (de)
KR (1) KR0181940B1 (de)
CN (1) CN1080304C (de)
AT (1) ATE159031T1 (de)
AU (3) AU5972890A (de)
CA (1) CA2021762C (de)
DE (1) DE69031556T2 (de)
DK (1) DK0414374T3 (de)
ES (1) ES2109921T3 (de)
FI (1) FI903721A7 (de)
GR (1) GR3025819T3 (de)
HK (1) HK1003032A1 (de)
HU (1) HU216013B (de)
IE (1) IE902690A1 (de)
IL (1) IL95153A0 (de)
MA (1) MA21911A1 (de)
NO (1) NO304268B1 (de)
NZ (1) NZ234615A (de)
PL (1) PL168597B1 (de)
PT (1) PT94791B (de)
SG (1) SG48175A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02501186A (ja) * 1987-06-22 1990-04-26 メディコ　ラブス　アクチェンゲゼルシャフト 異種ウイルス性ペプチド粒子の免疫原
PL168408B1 (pl) * 1989-08-03 1996-02-29 Smithkline Beecham Biolog Sposób wytwarzania stransformowanego mikroorganizmu PL
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
IL101651A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Hepatitis b virus surface proteins with reduced host carbohydrate content
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
UA40596C2 (uk) 1992-05-23 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини та спосіб її одержання
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
EP0637631A3 (de) * 1993-07-30 1996-08-21 Immuno Ag Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5658579A (en) * 1995-07-31 1997-08-19 The Procter & Gamble Company Cosmetic powder compositions having improved skin coverage
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
KR100372233B1 (ko) * 1997-03-12 2003-06-11 주식회사 코리아나화장품 미백 파우더, 그의 제조방법 및 그를 함유하는 메이크업 미백 화장료
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
JP2002534438A (ja) * 1999-01-12 2002-10-15 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規治療法
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
ATE516306T1 (de) 2003-08-13 2011-07-15 Novartis Vaccines & Diagnostic Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
EP1871411A4 (de) * 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Expression von hepatitis-b-virus-oberflächenantigen für impfstoffherstellung
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8956625B2 (en) 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
DK2086582T3 (da) 2006-10-12 2013-02-04 Glaxosmithkline Biolog Sa Vaccine omfattende en olie-i-vand-emulsionsadjuvans
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
CN102038948B (zh) * 2009-10-10 2013-04-10 复旦大学 一种控制乙型肝炎病毒持续性感染的疫苗
JPWO2011046218A1 (ja) * 2009-10-16 2013-03-07 株式会社カネカ 抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体
KR101958753B1 (ko) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 ｃｄ27에 결합하는 항체 및 이의 용도
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN103087933B (zh) * 2011-11-08 2015-07-22 北京生物制品研究所 一种重组多形汉逊酵母菌及其制备方法
EP2811981B1 (de) 2012-02-07 2019-05-08 Infectious Disease Research Institute Verbesserte hilfsstoffformulierungen mit tlr4-agonisten und verwendungsverfahren dafür
CN102643349B (zh) * 2012-04-17 2013-12-18 中国医学科学院医学生物学研究所 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
EP3711768A1 (de) 2013-04-18 2020-09-23 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
CN105797151A (zh) * 2016-03-25 2016-07-27 汪和睦 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗
EP3445783A2 (de) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistische antikörper zur bindung von humanem cd40 und verwendungen davon
IL263030B2 (en) 2016-05-16 2024-11-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
KR102392974B1 (ko) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Tlr 작용제를 함유하는 제제 및 사용 방법
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
ES3003260T3 (en) 2017-06-15 2025-03-10 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and uses thereof
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US20220016168A1 (en) 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
KR20240006541A (ko) 2021-04-09 2024-01-15 셀덱스 쎄라퓨틱스, 인크. Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288198A3 (de) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Peptidherstellung

Also Published As

Publication number Publication date
PT94791B (pt) 1997-09-30
EP0414374A2 (de) 1991-02-27
AU714652B2 (en) 2000-01-06
CA2021762A1 (en) 1991-01-26
HK1003032A1 (en) 1998-09-30
IL95153A0 (en) 1991-06-10
NO903285D0 (no) 1990-07-24
DK0414374T3 (da) 1998-03-09
HU904615D0 (en) 1991-01-28
EP0414374B1 (de) 1997-10-08
AU7752894A (en) 1995-02-16
PL286209A1 (en) 1991-04-08
NZ234615A (en) 1992-12-23
SG48175A1 (en) 1998-04-17
HUT57266A (en) 1991-11-28
MA21911A1 (fr) 1991-04-01
NO304268B1 (no) 1998-11-23
FI903721A7 (fi) 1991-01-26
KR910003103A (ko) 1991-02-26
JPH0380083A (ja) 1991-04-04
NO903285L (no) 1991-01-28
PT94791A (pt) 1991-03-20
ES2109921T3 (es) 1998-02-01
DE69031556D1 (de) 1997-11-13
FI903721A0 (fi) 1990-07-24
EP0414374A3 (en) 1992-12-16
HU216013B (hu) 1999-04-28
CA2021762C (en) 2000-09-12
AU1896897A (en) 1997-06-19
PL168597B1 (pl) 1996-03-29
KR0181940B1 (ko) 1999-04-01
DE69031556T2 (de) 1998-05-14
GR3025819T3 (en) 1998-03-31
JP3069907B2 (ja) 2000-07-24
AU5972890A (en) 1991-01-31
IE902690A1 (en) 1991-02-27
CN1052331A (zh) 1991-06-19
CN1080304C (zh) 2002-03-06

Similar Documents

Publication Publication Date Title
ATE159031T1 (de) Antigene sowie verfahren zu deren herstellung
KR880009130A (ko) 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원
DE3584866D1 (de) Hybridpartikel-immunogene.
EP0271302A3 (de) T-Zell-Epitope von Hepatitis-B-Virus-Nukleocapsid-Protein
DE3280468D1 (de) Synthese von menschlichen Virusantigenen durch Hefe.
EP0401941A3 (de) Hepatitis B-Virus-Oberflächen-Antigen und seine Herstellung
PL279426A1 (en) Method of intensifying generation of antigenic hbv particles containing essentially s and pre s2 proteins
NZ206960A (en) Recombinant antigenic protein containing the amine acid sequence of an epitope of the circumsporozoite protein of a plasmodium species
EP0068719A3 (de) Desoxyribonukleine Säuren, deren Herstellung und Verwendung
EP0174444A3 (en) Hepatitis surface antigen particle vaccine
EP0864649A3 (de) Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
MY106731A (en) Novel antigens and methods therefor
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
DE2961060D1 (en) Antigenic composition useful as a vaccine or vaccine intermediate, and process for preparing same
EP1274851A4 (de) Für eine prozessierungskomponente aus der n-terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid
EP0293201A3 (de) Methode zur Impfung gegen Hepatitis-B-Virus
BEESLEY EXPRESSION OF HBCAG FUSION PROTEINS IN YEAST AND AN INVESTIGATION OF THEIR IMMUNOLOGICAL PROPERTIES (IMMUNOLOGY)
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee